| Literature DB >> 35844431 |
Mohamed Hussain Syed Abuthakir1, Munirah Abdullah Al-Dosary2, Ashraf Atef Hatamleh2, Hissah Abdulrahman Alodaini2, P Perumal3, Muthusamy Jeyam1.
Abstract
Trichophyton rubrum is one of the major disease causing pathogens in human; mainly it causes tinea pedis, tinea cruris and tinea corporis. Cytochrome P450 which considered to be an important protein that can impact ergosterol biosynthesis pathway. B. aegyptiaca is rich source of secondary metabolites with tremendous medicinal values and it has sweet pulp, leaves with spine, strong seed and oily kernel. The epicarp of the fruit was taken for this study to inhibit T. rubrum using in vitro and in silico techniques. The epicarp portion was extracted using various solvents and water. The anti-dermatophytic activity on T. rubrum of these extracts was assessed utilizing poison plate technique with 5 individual concentrations. The fractioned chloroform extract of epicarp had fully inhibited the growth of T. rubrum at 3 mg/ml. Further, the chloroform extract was subjected to LC-MS analysis, in total, 40 compounds were elucidated. Then, the derived compounds were included for predicting ADMETox properties using Qikprop module. From the analysis 40 compounds were identified to be eligible for docking process. Then the desirable compounds, drug Ketoconazole were subjected to docking analysis using Glide module of Schrödinger. It shows that Platyphylloside has better docking result than other compounds and drug Ketoconazole. Further, MD simulation was carried out for Ketoconazole-Cyp450 and Platyphylloside-CYP450 complexes using Desmond, Schrödinger. MD simulation study also confirmed that the Platyphylloside-CYP450 complex more stable. This study suggests that Platyphylloside may act as potential inhibitor and it could be further subjected to experimental analysis to inhibit the T. rubrum growth.Entities:
Keywords: ADME-Tox, Absorption, Distribution, Metabolism, Excretion and Toxicity; B.aegyptiaca, Balanites aegyptiaca; BLAST, Basic Local Alignment Search Tool; Balanites aegyptiaca; CYP450; MD simulation; NCBI, National Center for Biotechnology Information; Platyphylloside; T.rubrum, Tricgophyton rubrum; Trichophyton rubrum
Year: 2022 PMID: 35844431 PMCID: PMC9280311 DOI: 10.1016/j.sjbs.2022.03.017
Source DB: PubMed Journal: Saudi J Biol Sci ISSN: 2213-7106 Impact factor: 4.052
Fig. 1Antidermatophytic activity of various extracts of fruit epicarp on T. rubrum.
Effect of fruit epicarp of B. aegyptiaca on radial growth of Trichophyton rubrum.
| Conc. mg/ml | PE | HEX | CHL | EA | MET | WAT | DMET | DWAT |
|---|---|---|---|---|---|---|---|---|
| 1 | 28.33 ± 0.88 | 25.33 ± 0.66 | 18 ± 0.00 | 24 ± 0.00 | 30 ± 0.00 | 10.66 ± 0.66 | 10.66 ± 0.66 | 20.00 ± 0.00 |
| 2 | 22.00 ± 1.15 | 17.00 ± 0.57 | 12.33 ± 0.33 | 21 ± 0.57 | 21 ± 0.57 | 8.33 ± 0.33 | 8.33 ± 0.33 | 17.33 ± 0.66 |
| 3 | 16.00 ± 0.00 | 10.33 ± 0.33 | 6.00 ± 0.00 | 13.33 ± 0.66 | 18 ± 0.00 | 6.00 ± 0.00 | 4.00 ± 0.00 | 11.66 ± 0.33 |
| 4 | 13.33 ± 0.66 | 6.00 ± 0.00 | – | 10.33 ± 0.88 | 11.66 ± 0.33 | 4.00 ± 0.00 | – | 10.00 ± 0.00 |
| 5 | 10.66 ± 0.33 | 2.00 ± 0.00 | – | 6.66 ± 0.66 | 7.33 ± 0.66 | – | – | 8.00 ± 0.00 |
Radial growth expressed as Mean ± S.E.
Values are calculated using Bonferroni test and they are significant (P < 0.05).
Fig. 2Anti-dermatophytic activity of fractioned chloroform extract of B. aegyptiaca epicarp on T. rubrum C – control, D – DMSO, K – Ketoconazole, 1 – 1 mg/ml, 2 – 2 mg/ml, 3 – 3 mg/ml, 4 – 4 mg/ml, 5 – 5 mg/ml.
Fig. 3MIC of fractioned Chloroform extract on T. rubrum.
Phytochemical analysis of fractioned chloroform extract of B. aegypptiaca fruit epicarp.
| Groups | Name of the test | Presence/absence* | |
|---|---|---|---|
| 1. | Proteins and Amino acids | 1.Biuret Test | + |
| 2. | Carbohydrates | 1.Benedict’s Test | + |
| 3. | Flavonoids | Alkaline reagent test | + |
| 4. | Phenols | Ferric chloride Test | + |
| 5. | Tannins | Ferric chloride test | – |
| 6. | Alkaloids | Mayer’s Test | + |
| 7. | Terpenoids | Salkowiski’s test | + |
| 8. | Steroids | Liebermann Burchard test | + |
| 9. | Saponins | Froth Test | + |
| 10. | Anthraquinones Glycosides | Borntrager’s test | – |
| 11. | Coumarins | Coumarin Test | – |
| 12. | Emodins | Emodin test | – |
(+) – Presence (−) – Absence.
Fig. 4Chromatogram of LC-MS evaluation of fractioned chloroform extract of fruit epicarp with both positive (above) and negative (below) mode.
LC-MS derived compounds from fractioned chloroform extract of epicarp of Balanites aegyptiaca.
| Compound name | Mass from LC-MS | Original mass (GNPS) | Chemical formula | Ion mode | |
|---|---|---|---|---|---|
| 1. | Theobromine | 180.08 | 180.0647 | C7H8N4O2 | + |
| 2. | N-Acetyl Phenylalanine | 207.08 | 207.0895 | C11H13NO3 | + |
| 3. | Aerugine | 209.11 | 209.0510 | C9H15N5O | + |
| 4. | N-Acetyl-D-Galactosamine | 221.11 | 221.0899 | C8H15NO6 | + |
| 5. | Forchlorfenurone | 247.07 | 247.0512 | C12H10ClN3O | + |
| 6. | 3-[(E)-2-(3-Hydroxyphenyl)vinyl]-5-methoxyphenol | 242.16 | 242.0943 | C15H14O3 | + |
| 7. | p-Coumaric acid | 164.19 | 164.0473 | C9H8O3 | + |
| 8. | 7-methoxy-9,10-dihydrophenanthrene-2,5-diol | 242.10 | 242.0943 | C15H14O3 | + |
| 9. | N ∼ 5 ∼ -Carbamoyl-N ∼ 2∼-(phenylacetyl)ornithine | 293.08 | 293.1376 | C14H19N3O4 | + |
| 10. | Glucosaminate | 195.10 | 195.0743 | C6H13NO6 | + |
| 11. | Caffeate | 180.05 | 180.0423 | C9H8O4 | + |
| 12. | Phenylalanine | 164.09 | 165.0790 | C9H11NO2 | + |
| 13. | Lycorine | 287.09 | 287.1158 | C16H17NO4 | + |
| 14. | Paraxanthine | 180.09 | 180.0647 | C7H8N4O2 | + |
| 15. | Adenosine | 267.10 | 267.0968 | C10H13N5O4 | + |
| 16. | N-methylaurotetanine | 341.13 | 341.1627 | C20H23NO4 | + |
| 17. | 1,3,6-trihydroxy-5-methoxy-2-[(2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]xanthen-9-one | 437.11 | 436.1006 | C20H20O11 | + |
| 18. | N-[2-(4- | 353.20 | 353.1838 | C18H27NO6 | + |
| 19. | Allocryptopine | 369.45 | 369.1576 | C21H23NO5 | + |
| 20. | Pentaleno[1,6a-c]pyran-9-carboxylic acid, 1,3,4,5,6,7,7a,9a-octahydro-4,6,6-trimethyl-3-oxo-, (4S,4aR,7aS,9aR)- | 264.14 | 264.1362 | C15H20O4 | + |
| 21. | 2-[5-[2-[2-[5-(2-oxopropyl)oxolan-2-yl]propanoyloxy]butyl]oxolan-2-yl]propanoic acid | 398.26 | 398.2305 | C21H34O7 | + |
| 22. | Deoxycytidine | 227.11 | 227.0906 | C9H13N3O4 | – |
| 23. | Pulvinic acid | 308.12 | 308.0410 | C18H12O5 | – |
| 24. | 2-hydroxy-4-methoxy-3-(3-methylbut-2-enyl)-6-(2-phenylethyl)benzoic acid | 341.13 | 340.1675 | C21H24O4 | – |
| 25. | Divaricatinic acid | 211.08 | 210.0892 | C11H14O4 | – |
| 26. | Cortisol | 362.20 | 362.2093 | C21H30O5 | – |
| 27. | Norepanorin | 421.15 | 421.1525 | C24H23NO6 | – |
| 28. | 5-Chlorodivaricatinic acid | 245.12 | 244.0502 | C11H13ClO4 | – |
| 29. | Citreorosein | 285.11 | 286.0477 | C15H10O6 | – |
| 30. | 5-hydroxy-7-[4-hydroxy-2-methoxy-3-(3-methylbut-2-enyl)phenyl]-2,2-dimethyl-7,8-dihydropyrano[3,2-g]chromen-6-one | 437.11 | 436.1886 | C26H28O6 | – |
| 31. | 2-{[6-O-(beta-D-Glucopyranosyl)-beta-D-glucopyranosyl]oxy}-2-phenylacetamide | 475.29 | 475.1690 | C20H29NO12 | – |
| 32. | Tetradecanoic acid | 228.11 | 228.2089 | C14H28O2 | – |
| 33. | Hexadecanoic acid | 256.17 | 256.2402 | C16H32O2 | – |
| 34. | Platyphylloside | 476.19 | 476.2050 | C25H32O9 | – |
| 35. | (3E)-7-Hydroxy-3,7-dimethyl-3-octen-1-yl 6-O-(6-deoxy-alpha-L-mannopyranosyl)-beta-D-glucopyranoside | 481.22 | 480.2571 | C22H40O11 | – |
| 36. | N-Acetyl Neuraminate | 309.12 | 309.1060 | C11H19NO9 | – |
| 37. | 11-eicosenoic acid | 311.16 | 310.2872 | C20H38O2 | – |
| 38. | 4-[(2-{[(2-Ethyl-2,3-dihydroxybutanoyl)oxy]methyl}phenyl)amino]-4-oxobutanoic acid | 353.20 | 353.1475 | C17H23NO7 | – |
| 39. | Thelephoric acid | 351.19 | 352.0219 | C18H8O8 | – |
| 40. | (3S,5S,8R,9S,10S,13R,14S,17R)-3-[(2R,3R,4S,5R,6S)-3,4-dihydroxy-6-methyl-5-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-5,14-dihydroxy-13-methyl-17-(6-oxopyran-3-yl)-2,3,4,6,7,8,9,11,12,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthrene-10-carbaldehyde | 724.46 | 724.3305 | C36H52O15 | – |
Fig. 53D structure of Modeled Cytochrome P450 protein.
Fig. 6Ramachandran plot analysis of modeled Cytochrome P450 protein.
Fig. 7Predicting active site residues of CYP450 protein using multiple sequence alignment.
Docking result of drug Ketoconazole and LC-MS compounds from epicarp of B. aegyptiaca with Cytochrome P450 protein.
| Compound name | Dock score (kcal/mol) | Interacting residues | Bond length (Å) | |
|---|---|---|---|---|
| 1. | Platyphylloside | −13.2 | Tyr 106, Lys 131, Pro 447, Phe 448, His 453(2), Phe 496 | 5.39, 1.82, 1.78, 2.24, 1.84, 2.17, 5.48 |
| 2. | (3E)-7-Hydroxy-3,7-dimethyl-3-octen-1-yl 6-O-(6-deoxy-alpha-L-mannopyranosyl)-beta-D-glucopyranoside | −12.6 | Tyr 106, Tyr 120, His 365, Ser 366, Tyr 492 | 2.03, 2.36, 1.95, 1.63, 1.714 |
| 3. | 1,3,6-trihydroxy-5-methoxy-2-[(2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]xanthen-9-one | −11.7 | Tyr 106, Tyr 120, Lys 131, His 453 | 4.28, 1.79, 2.16, 1.88 |
| 4. | 2-{[6-O-(beta-D-Glucopyranosyl)-beta-D-glucopyranosyl]oxy}-2-phenylacetamide | −11.2 | Pro 447(2), Phe 448, His 453, Ile 464 | 2.05,2.31, 1.94, 2.07, 2.03 |
| 5. | 5-hydroxy-7-[4-hydroxy-2-methoxy-3-(3-methylbut-2-enyl)phenyl]-2,2-dimethyl-7,8-dihydropyrano[3,2-g]chromen-6-one | −10.5 | – | – |
| 6. | 4-[(2-{[(2-Ethyl-2,3-dihydroxybutanoyl)oxy]methyl}phenyl)amino]-4-oxobutanoic acid | −10.1 | Tyr 106, Tyr 120, Ser 366(2), Arg 389, Phe 496 | 2.10, 2.15, 1.63, 2.44, 2.34, 5.37 |
| 7. | N-[2-(4- | −10.0 | Tyr 106, Tyr 120, His 453(2) | 5.02, 2.29, 1.71, 1.75 |
| 8. | Cortisol | −9.9 | Tyr 106, Ser 366 | 2.49, 2.13 |
| 9. | 2-[5-[2-[2-[5-(2-oxopropyl)oxolan-2-yl]propanoyloxy]butyl]oxolan-2-yl]propanoic acid | −9.2 | Tyr 106, Arg 369 | 2.17, 2.78 |
| 10. | Thelephoric acid | −9.0 | Leu 495 | 1.94 |
| 11. | Citreorosein | −8.8 | Tyr 106, Ser 366 | 2.09, 1.72 |
| 12. | 7-methoxy-9,10-dihydrophenanthrene-2,5-diol | −8.4 | Tyr 106, Ser 366 | 4.09, 1.84 |
| 13. | 2-hydroxy-4-methoxy-3-(3-methylbut-2-enyl)-6-(2-phenylethyl)benzoic acid | −8.2 | Tyr 120, His 453(2) | 1.98, 1.75, 2.72 |
| 14. | Lycorine | −8.2 | Tyr 106, Ser 366, Leu 495 | 4.28, 2.00, 2.42 |
| 15. | 3-[(E)-2-(3-Hydroxyphenyl)vinyl]-5-methoxyphenol | −8.2 | Tyr 120, Leu 495 | 1.94, 1.74 |
| 16. | 11-eicosenoic acid | −8.1 | Tyr 120, His 453 | 1.81, 1.94 |
| 17. | Norepanorin | −8.1 | Tyr 106, Tyr 120 | 4.03, 2.09 |
| 18. | Deoxycytidine | −7.9 | Tyr 106(2), Ser 366 | 2.10, 5.37, 1.69 |
| 19. | Pentaleno[1,6a-c]pyran-9-carboxylic acid, 1,3,4,5,6,7,7a,9a-octahydro-4,6,6-trimethyl-3-oxo-, (4S,4aR,7aS,9aR) | −7.7 | Arg 369 | 4.57 |
| 20. | N-Acetylneuraminate | −7.7 | Ser 366, Leu 495 | 1.75, 1.89 |
| 21. | N-methylaurotetanine | −7.5 | His 453, Phe 496 | 2.03, 5.36 |
| 22. | Forchlorfenuron | −7.2 | Tyr 106, Tyr 120(2) | 5.33, 2.16, 2.20 |
| 23. | N-Acetyl Phenylalanine | −7.1 | Tyr 106 | 1.83 |
| 24. | Allocryptopine | −7.0 | – | – |
| 25. | Caffeate | −6.9 | Ser 366(2) | 1.99, 2.03 |
| 26. | Pulvinic acid | −6.8 | – | – |
| 27. | Adenosine | −6.8 | Tyr 106, Tyr 120, Ser 366 | 2.34, 2.61, 1.85 |
| 28. | N-Acetyl-D-Galactosamine | −6.7 | Tyr 106, Ser 366 | 2.10, 1.68 |
| 29. | N ∼ 5 ∼ -Carbamoyl-N ∼ 2∼-(phenylacetyl)ornithine | −6.7 | Tyr 106, His 453 | 4.06, 1.77 |
| 30. | Divaricatinic acid | −6.6 | Leu 495 | 2.16 |
| 31. | Glucosaminate | −6.2 | Tyr 120, Lys 131, His 453(2) | 1.69, 1.94, 2.04, 2.16 |
| 32. | 5-Chlorodivaricatinic acid | −6.1 | – | – |
| 33. | Aerugine | −5.9 | Tyr 120 | 2.07 |
| 34. | p-Coumaric acid | −5.9 | Ser 366 | 1.92 |
| 35. | Paraxanthine | −5.9 | Tyr 106, Leu 495 | 2.48, 1.81 |
| 36. | Phenylalanine | −5.4 | Tyr 106, Phe 496 | 2.19, 6.19 |
| 37. | Theobromine | −5.1 | Tyr 106(2), Phe 496 | 2.17, 4.80, 5.08 |
| 38. | Hexadecanoic acid | −5.0 | Tyr 120, His 453 | 2.08, 1.81 |
| 39. | Tetradecanoic acid | −4.3 | Tyr 120, His 453 | 2.03, 1.81 |
Fig. 8Docking result of CYP450 with (a) drug Ketoconazole, (b) Platyphylloside.
Fig. 9MD simulation result of complex structure of CYP450 with Platyphylloside (a) Protein-Ligand RMSD, (b) Protein RMSF, (c) Protein-Ligand interactions, (d) Protein-Ligand contacts, (e) 2D diagram of interactions at 10th ns.
Fig. 10MD simulation result of complex structure of CYP450 with Ketoconazole (a) Protein-Ligand RMSD, (b) Protein RMSF, (c) Protein-Ligand interactions, (d) Protein-Ligand contacts, (e) 2D diagram of interactions at 10th ns.